The Dermatology Digest

MARCH 10, 2024

55% of people experienced clinically meaningful itch relief ( Peak Pruritus Numerical Rating Scale ≥4-point improvement) §. 55% of people experienced clinically meaningful itch relief ( Peak Pruritus Numerical Rating Scale ≥4-point improvement) §. No new safety signals were observed and there were no serious adverse events reported.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

JANUARY 23, 2024

The research was presented by Jonathan I Silverberg, MD, Associate Professor of Dermatology and Director of Clinical Research and Contact Dermatitis at The George Washington University School of Medicine in Washington, DC, during the late breaker session at Maui Derm 2024. Safety was assessed throughout the study.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. or less,” says Dr. Guttman-Yassky, the Director of the Occupational Dermatitis Clinic and Director of the Laboratory for Inflammatory Skin Diseases.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. However, there are concerns about the safety of using retinol on younger skin due to the physiological differences between children’s and adults’ skin.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

The Dermatology Digest

JULY 25, 2024

The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or without TCI, in adolescent and adult patients with moderate-to-severe AD.

Dermatitis 36

Dermatitis Safety Eczema Clinic 36

The Dermatology Digest

MARCH 11, 2024

The new findings support the quarterly dosing of amlitelimab 250mg with a 500mg loading dose (LD) now being investigated in a larger Phase 3 clinical program (OCEANA). Moreover, high responder rates were also observed in participants who were taken off amlitelimab. This could offer an important benefit in the treatment of AD patients.”

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

Tricoci University

APRIL 19, 2024

Higher levels of stress are correlated to inflammation, which can manifest in acne, eczema, and psoriasis flare-ups. Diverse Skincare Matters There have been rumors that the FDA is changing its guidelines to require clinical trials on the darkest skin tones on the Fitzpatrick scale.

Esthetics 52

Esthetics Skincare Fitzpatrick Scale Aromatherapy 52

Eminence Organics

JULY 3, 2024

In comparison, facial razors are tools that feature a safety guard and sit on the skin at a 35-degree angle and were designed to be used at home. Dermaplaning Regret #2: Your Breakouts Worsen According to the Cleveland Clinic , the sliding motion of dermaplaning can make breakouts worse by spreading bacteria around.

Dermaplaning 81

Dermaplaning Hair Removal Tools Facials 81

The Dermatology Digest

OCTOBER 5, 2023

The DNA Connection Deep in our DNA, there’s a primordial theme of slowing down, connection, and safety, said Dr. Barr. You can be activated…like falling behind in the clinic or navigating a challenging patient interaction and you can ride the wave of your stress response and stay within what we call ‘the window of capacity.’”

Safety 36

Safety Social Media Therapy Sun Protection 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. Clear translation of evidence to clinically actionable and contextual recommendations, and novel approaches to facilitate knowledge translation were paramount. Suggest against elimination diets for AD.

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

Aesthetics Advisor

JUNE 18, 2024

"The eyelids are very vascular, and the eyelid skin is very thin; this will make them more apparent under the eyelid skin and cause the appearance of dark circles," Miss Elizabeth Hawkes, consultant ophthalmic and oculoplastic surgeon at London's Cadogan Clinic, told POPSUGAR.

Vitamin C 36

Vitamin C Extractions Hydration Makeup 36

Lydia Sarfati

MARCH 13, 2024

A recently published study from the Cleveland Clinic shows that integrative therapies that include massage therapy, can improve the physical, mental and social health for patients with chronic, non-cancer related pain without increased use of opioid medications.

Facial Massage 45

Facial Massage Facials Surgery Tools 45

The Dermatology Digest

MARCH 7, 2024

The drug demonstrated significant and clinically relevant improvements in itch, patient-assessed quality-of-life indicators, inflammation, and safety, with minimal side effects and strong patient tolerability when compared to baseline.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The open-label, single-center Phase 2 clinical trial of ADX-629 included eight mild-to-moderate AD patients.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

AUGUST 30, 2024

The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure. The clade I variant of mpox is characterized by more severe clinical outcomes and a higher case fatality rate.

Portfolios 73

Portfolios Tools Eczema Safety 73

First Derm

DECEMBER 26, 2023

Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a. Eczema (Dermatitis): Symptoms : Red, itchy, scaly patches on the scalp. 7] Triggers and Aggravators Common for Eczema and Psoriasis : Stress, hormonal changes, and environmental factors.

Management 64

Management Dermatitis Eczema Consultation 64

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

JANUARY 8, 2024

Based on these data, AbbVie will advance its clinical program of lutikizumab in HS to Phase 3. Kimball, MD, MPH, a professor of Dermatology at Harvard Medical School and the President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, in a news release. in the placebo group.

Medical 36

Medical Clinic Therapy Eczema 36

The Eco Well Blog

MAY 8, 2023

Her area of clinical expertise is in complex medical dermatology, skin cancer, and acne. He’s held key R&D, regulatory, quality, product safety, clinical & scientific affairs positions at Ciba, Dial, Henkel, ITG Brands, Newell Rubbermaid.

Legal 52

Legal Technology Sun Protection Branding 52